Spicer Seth, Brancaccio Hanna, Sundin Ashley, Bono Jamie, DesRochers John, Goodwin Brandon, Averell Nicholas, Park Seungkyu, Goodwin Alexandra, DiCiurcio William, Jermyn Richard
Department of Medicine, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.
Future Forward Research Institute, Toms River, NJ, USA.
Hip Int. 2025 Jul;35(4):392-401. doi: 10.1177/11207000251337403. Epub 2025 May 15.
The objective of this study was to determine the effect of bone marrow aspirate concentrate (BMAC) on long-term patient outcomes when used as an adjuvant to acetabular repair of the labrum.
A systematic review and meta-analysis were completed following PRISMA 2020 guidelines. Included in the analysis were controlled studies which assessed functional outcomes via the International Hip Outcome Tool-33 (iHOT-33) 12 or 24 months after acetabular repair with BMAC adjunct. 4 studies totaling 315 participants were analysed.
Pooled effect sizes for iHOT-33 scores were not significantly different between control and treatment groups at 12 ( 0.14, Cohen's D ≏ 0.79) or 24 months ( 0.30, Cohen's D ≏ 0.56).
Non-significant trends in favour of BMAC augmentation were found in this study. However, the trends reported are promising and warrant further investigation with further randomised controlled trials.
本研究的目的是确定当骨髓抽吸浓缩物（BMAC）用作髋臼盂唇修复辅助手段时对患者长期预后的影响。
按照PRISMA 2020指南完成了一项系统评价和荟萃分析。纳入分析的是对照研究，这些研究在使用BMAC辅助进行髋臼修复12或24个月后，通过国际髋关节预后工具-33（iHOT-33）评估功能预后。共分析了4项研究，总计315名参与者。
在12个月时（效应量为0.14，科恩d值约为0.79）和24个月时（效应量为0.30，科恩d值约为0.56），对照组和治疗组的iHOT-33评分合并效应量无显著差异。
本研究发现了有利于BMAC增强的非显著趋势。然而，所报告的这些趋势很有前景，值得通过进一步的随机对照试验进行进一步研究。
